Wide Ranks

IVVD

Invivyd, Inc.

0.6742

Top Statistics
Market Cap 80 M Forward PE -5.19 Revenue Growth 0.00 %
Current Ratio 4.71 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA 0.2510 Enterprise / Revenue -23.31 Price To Sales Trailing12 Months 35.62
Profitability
Profit Margins 0.00 % Operating Margins -2175.22 %
Balance Sheet
Total Cash 147 M Total Cash Per Share 1.24 Total Debt 681000
Total Debt To Equity 0.4840 Current Ratio 4.71 Book Value Per Share 1.61
All Measures
Short Ratio 2371.00 % Message Board Id finmb_677282690 Shares Short Prior Month 6 M
Return On Equity -0.9656 City Waltham Uuid 3adfb3ee-a95c-378e-a775-62d905e5aca0
Previous Close 0.5900 First Trade Date Epoch Utc 1 B Book Value 1.61
Beta 0.6560 Total Debt 681000 Volume 2 M
Price To Book 0.4185 Fifty Two Week Low 0.5800 Total Cash Per Share 1.24
Total Revenue 2 M Shares Short Previous Month Date 1 B Target Median Price 9.00
Audit Risk 7 Max Age 86400 Recommendation Mean 1.80
Sand P52 Week Change 0.3133 Operating Margins -2175.22 % Target Mean Price 6.51
Net Income To Common -203836992 Short Percent Of Float 0.1050 Implied Shares Outstanding 119 M
Trailing Peg Ratio None Last Fiscal Year End 1 B Average Daily Volume10 Day 1 M
Average Volume10days 1 M Total Cash 147 M Next Fiscal Year End 1 B
Revenue Per Share 0.0200 Held Percent Insiders 0.1817 Trailing PE 0.0000
Date Short Interest 1 B Most Recent Quarter 1 B Share Holder Rights Risk 6
Regular Market Previous Close 0.5900 Target Low Price 1.00 Gmt Off Set Milliseconds -18000000
Fifty Day Average 0.9360 Open 0.6241 Free Cashflow -115914496
State MA Dividend Yield 0.00 % Return On Assets -0.5356
Time Zone Short Name EST Board Risk 5 Trailing Eps -1.95
Day Low 0.6235 Address1 1601 Trapelo Road Shares Outstanding 119 M
Compensation Risk 9 Price Hint 4 Target High Price 10.00
Website https://invivyd.com 52 Week Change -0.5595 Average Volume 518528
Forward Eps -0.2000 Recommendation Key buy Compensation As Of Epoch Date 1 B
Quick Ratio 412.50 % Is_sp_500 False Regular Market Day High 0.7818
Profit Margins 0.00 % Debt To Equity 0.4840 Fifty Two Week High 5.20
Day High 0.7818 Shares Short 8 M Regular Market Open 0.6241
Industry Key biotechnology Earnings Growth 0.00 % Enterprise To Revenue -23.31
Revenue Growth 0.00 % Shares Percent Shares Out 0.0693 Operating Cashflow -186404992
Currency USD Time Zone Full Name America/New_York Market Cap 80 M
Is_nasdaq_100 False Zip 02451 Quote Type EQUITY
Industry Biotechnology Long Name Invivyd, Inc. Overall Risk 7
Regular Market Day Low 0.6235 Held Percent Institutions 0.7925 Current Price 0.6742
Address2 Suite 178 Enterprise To Ebitda 0.2510 Financial Currency USD
Current Ratio 4.71 Gross Margins 96.11 % Industry Disp Biotechnology
Number Of Analyst Opinions 5 Country United States Float Shares 45 M
Two Hundred Day Average 1.83 Governance Epoch Date 1 B Enterprise Value -52780596
Price To Sales Trailing12 Months 35.62 Forward PE -5.19 Regular Market Volume 2 M
Ebitda -210659008 Exchange NGM
Go to Yahoo Finance Go to Seeking Alpha 
Invivyd, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States.

The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.

Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.

The company also has discovery stage candidates for the prevention of seasonal influenza and COVID-19.

It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses.

The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022.

Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.